Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated <i>BRAF</i> V600E-Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study.

J, Tabernero; A, Grothey; Cutsem E, Van; R, Yaeger; H, Wasan; T, Yoshino; J, Desai; F, Ciardiello; F, Loupakis; YS, Hong; N, Steeghs; TK, Guren; HT, Arkenau; P, Garcia-Alfonso; E, Elez; A, Gollerkeri; K, Maharry; J, Christy-Bittel; S, Kopetz

doi:10.1200/jco.20.02088

Public

Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated <i>BRAF</i> V600E-Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study.

Shared by NobleBlocks on Feb 1, 2021 • 12:00 AM UTC

Authors:

Tabernero J

Grothey A

Van Cutsem E

Abstract

<h4>Purpose</h4>BEACON CRC evaluated encorafenib plus cetuximab with or without binimetinib versus investigators' choice of irinotecan or FOLFIRI plus cetuximab in patients with <i>BRAF</i>V600E-mutant metastatic colorectal cancer (mCRC), after progression on 1-2 prior regimens. In the previously re...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!